Dr. Lau is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E 34th St
Fl 8
New York, NY 10016Phone+1 212-404-3696
Education & Training
University of British ColumbiaClass of 2013
Certifications & Licensure
NY State Medical License 2021 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Daratumumab in STK11 Mutated NSCLC Start of enrollment: 2023 Jun 01
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated...Jacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, Kelly G Paulson, Hossein Borghaei
Cancer. 2025-02-01 - Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patients.Yuchen Li, Jennifer Law, Lisa W Le, Janice J N Li, Christopher Pettengell
Lung Cancer. 2025-01-01 - 6 citationsCTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2024-11-01
Press Mentions
Tarlatamab plus PD-L1 Inhibitor as Potential First-Line Maintenance for Extensive-Stage Small Cell Lung CancerOctober 8th, 2024- TKI plus Chemotherapy Prolonged Survival Outcomes in NSCLC with Brain MetastasesFebruary 22nd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
